rethinkTHC Search
Menu
Study breakdown

Review of 10 clinical trials supports CBD effectiveness for Dravet syndrome in children

ReviewModerate evidence
The takeaway

A narrative review of 10 clinical trials found CBD (Epidiolex) effective in reducing seizure frequency in pediatric Dravet syndrome patients, with manageable side effects and important drug interactions.

Pediatric neurologists, families of children with Dravet syndrome, and epilepsy researchers.

10 clinical trials support CBD efficacy in pediatric Dravet syndrome

What the researchers found

Across 10 clinical trials, CBD demonstrated efficacy in reducing seizure frequency in children with Dravet syndrome. Common adverse events included somnolence, diarrhea, and decreased appetite. Interactions with clobazam were clinically significant.

Why it matters

Dravet syndrome is among the most severe childhood epilepsies with limited treatment options. CBD (Epidiolex) was the first cannabis-derived drug approved for this condition, and this review consolidates the clinical evidence.

The numbers in context

10 clinical trials reviewed. CBD reduced seizure frequency in Dravet syndrome. Common side effects: somnolence, diarrhea, decreased appetite. Clobazam interaction significant.

How the study worked

Narrative review of 10 clinical trials evaluating CBD efficacy and safety in pediatric Dravet syndrome patients.

What this study cannot tell us

Narrative review without systematic methodology or quantitative synthesis. Most trials used specific pharmaceutical-grade CBD (Epidiolex) at defined doses, which may not generalize to other CBD products. Focus on Dravet syndrome only.

How to read the evidence

Narrative review of clinical trials including RCTs. Provides useful summary but without quantitative synthesis.

When this study was published

Published 2023.

The bigger picture

The FDA approval of Epidiolex for Dravet syndrome was a landmark for cannabinoid medicine. This review confirms the evidence base supporting that decision and highlights ongoing safety considerations.

Questions still open

  • Is CBD effective long-term beyond the trial durations studied? Should the clobazam-CBD interaction be leveraged therapeutically or minimized?

Common questions

Does CBD work for Dravet syndrome?
Yes. This review of 10 clinical trials confirms that pharmaceutical CBD (Epidiolex) reduces seizure frequency in children with Dravet syndrome. The evidence supported FDA approval for this indication. Side effects are generally manageable but require monitoring.
What are the side effects of CBD in Dravet syndrome?
The most common side effects across trials were somnolence (sleepiness), diarrhea, and decreased appetite. The interaction between CBD and clobazam (a commonly co-prescribed seizure medication) is clinically important, as it can increase both efficacy and side effects.

Read the original research

The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.

European journal of medical research, 29(1), 182

Citation

Aderinto, Nicholas; Olatunji, Gbolahan; Kokori, Emmanuel; Ajayi, Yusuf Ismaila; Akinmoju, Olumide; Ayedun, Abiola Samuel; Ayoola, Oluwapelumi Ikeoluwa; Aderinto, Noah Oluwaseun. (2024). The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.. European journal of medical research, 29(1), 182. https://doi.org/10.1186/s40001-024-01788-6

Explore the wider topic